*Articles from the former Asklep
ASKLEP Inc., a Japan CRO with headquarters in Tokyo, is pleased to announce the opening of their first overseas subsidiary in Shanghai China, that will further enhance clinical services and business expansion in the Asian region.
With the globalization of clinical development, ASKLEP has already executed strategic partnership agreements with CROs in Europe, North America, Taiwan, and Korea. In particular, ASKLEP sees the Asian territory as a high growth region for clinical development and has been actively developing services and geographic coverage to meet those needs.. .
Growth for China in the pharmaceutical industry is expected to exceed two trillion yen, and China’s participation in Asian clinical trials is also expected to grow dramatically. In June 2010, ASKLEP established a representative office in Shanghai, China as a base of operations for conducting clinical trials in China.
By establishing a local subsidiary, ASKLEP aims to acquire market share in China’s developing clinical market and to include Japan in studies being conducted in China. ASKLEP’s goal is to expand its business by utilizing local networks and local management expertise. This follows our concept of “Think Global Act Local”.
ASKELP expects multi-national and Japanese pharmaceutical and device companies to continue increasing trial activities in China. We plan to be there not only to support these clients, but also local Chinese pharmaceutical companies as well.
About ASKLEP China
|Company name||ASKLEP CHINA Inc.|
|Headquarters||Huangpu, Shanghai China|
|Capital||$500,000 USD (ASKLEP: 100%)|
|Representatives||Chairman Yuichi Yahagi|
|Director and General Manager||Hozui Imatsu|
|Start of Operations||December 1, 2010 (projecting)|